PORTLAND, Maine–(BUSINESS WIRE)–MedRhythms, a leader in developing prescription digital therapeutics that use sensors, software, and music to measure and improve walking for patients with a neurologic injury or disease, today announced the closing of a Series B extension round, with investment from one of Japan’s largest venture capital companies Global Brain with its CVC JGC MIRAI Innovation Fund, and Bose Ventures. The follow-on investment brings the Company’s total Series B financing to $27 million, an increase from their announcement in July. Read more
MedRhythms Announces Addition of Global Brain Corporation and Bose Ventures to Series B Round
Related Posts
UMaine professor McGill receives top German research award
ORONO — University of Maine ecology professor Brian McGill was awarded the Humboldt Research Award, one of the most prestigious scientific...
Four Maine workforce programs could get $6.5M in fed funding
Four workforce training programs in Maine could receive nearly $6.5 million in federal funding through the markup of the fiscal year 2024 financial...
Music as medicine: FDA approves stroke damage therapy from Portland startup
Doctors may soon start writing an unconventional prescription to help stroke survivors regain their ability to walk: music. MedRhythms, a Portland...